Schizo Affective Disorder Clinical Trial
— ATMSSlowingOfficial title:
Optimizing rTMS for Psychomotor Slowing in Psychosis (ATMSSlowing) - A 1-week, Non-randomised Clinical Trial of add-on Accelerated Repetitive Transcranial Magnetic Stimulation for Psychomotor Slowing in Psychosis
The goal of this clinical trial is to optimize the treatment of psychomotor slowing in patients with schizophrenia using Transcranial Magnetic Stimulation (TMS). A previous randomized controlled trial indicated that inhibitory stimulation over the supplementary motor area (SMA) once daily over 3 weeks ameliorates psychomotor slowing. In this trial the investigators use a shorter inhibitory protocol called cTBS and to be applied 3 times per day. This should lead to faster treatment response and less burden to patients. The main question the investigators aim to answer are: Can the treatment with cTBS 3 times per day ameliorate psychomotor slowing in schizophrenia over one week? Participants will complete questionnaires on the first and last day of the study. Each day, participants will receive the TMS-treatment. Optionally, participants can receive a cerebral MRI before the study and/or come for an additional day 6 to repeat some of the questionnaires. There is no comparison group. All participants will receive the same treatment.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | September 2025 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - 18-60 years. - Ability and willingness to participate in the study - Ability to provide written informed consent - Informed Consent as documented by signature (Appendix Informed Consent Form) - Schizophrenia spectrum disorders according to DSM-5 with psychomotor slowing (SRRS score = 15). Exclusion Criteria: - Substance abuse or dependence other than nicotine. - Past or current medical or neurological conditions associated with impaired or aberrant movement, such as brain tumors, stroke, M. Parkinson, M. Huntington, dystonia. - Severe head trauma with subsequent loss of consciousness. - Epilepsy or other convulsions. - History of any hearing problems or ringing in the ears. - Standard exclusion criteria for TMS (implanted electronic devices (e.g. pacemakers, implantable cardioverter-defibrillators, vagus nerve stimulators and wearable cardioverter-defibrillators, ocular implants, deep brain stimulators, implanted medication pumps, intracardiac lines even when removed) and/or conductive objects near the coil (e.g. cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents and bullet fragments) - Women who are pregnant or breastfeeding. - Any TMS treatment in the past 2 months. - If applicable: standard exclusion criteria for MRI (study participation without MRI is possible) - Intention to become pregnant during the course of the study - Previous enrolment into the current study - Enrolment of the investigator, his/her family members, employees, and other dependent persons |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital of Psychiatry and Psychotherapy | Bern |
Lead Sponsor | Collaborator |
---|---|
University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of Treatment-Emergent Adverse Events as assessed by a safety questionnaire | After all TMS sessions of one day (after 3, 6, 9, 12, and 15 cTBS sessions) the investigators will apply a short safety questionnaire to assess the incidence of the most common side effects of TMS. | Daily between baseline and post at day 5 | |
Other | Incidence of spontaneously mentioned Treatment-Emergent Adverse Events | After each cTBS session, participants are inquired about stimulation side effects (Adverse Events and Device Deficiencies) with the unspecific question "was anything uncomfortable during the stimulation?". | Daily between baseline and post at day 5, and follow-up 1 week later | |
Other | Resting-state functional connectivity as a Biomarker of the severity of PS | Regression analyses between the clinical assessment of PS severity (assessed by the motor rating scales and the objective measurements) and the resting state functional connectivity (using resting-state BOLD fMRI) within the cerebral motor system | In the week before baseline | |
Other | Resting state cerebral perfusion as a Biomarker of the severity of PS | Regression analyses between the clinical assessment of PS severity (assessed by the motor rating scales and the objective measurements) and the resting state cerebral perfusion (using resting-state cerebral perfusion fMRI) within the cerebral motor system | In the week before baseline | |
Other | Structural connectivity as a Biomarker of the severity of PS | Regression analyses between the clinical assessment of PS severity (assessed by the motor rating scales and the objective measurements) and the structural integrity of the sensory motor pathway using the diffusion MRI data. | In the week before baseline | |
Other | Resting-state functional connectivity as a Biomarker of the response to cTBS | Comparison of the resting state functional connectivity (using resting-state BOLD fMRI) within the cerebral motor system between the patients who responded (evaluated with the % of change in SRRS) or not to cTBS | In the week before baseline | |
Other | Resting state cerebral perfusion as a Biomarker of the severity of PS | Comparison of the resting state cerebral perfusion (using resting-state cerebral perfusion fMRI) within the cerebral motor system between the patients who responded (evaluated with the % of change in SRRS) or not to cTBS | In the week before baseline | |
Other | Structural connectivity as a Biomarker of the severity of PS | Comparison of the structural integrity of the sensory motor pathway using the diffusion MRI data between the patients who responded (evaluated with the % of change in SRRS) or not to cTBS | In the week before baseline | |
Primary | Change in Salpetriere Retardation Rating Scale (SSRS) from baseline | Changes in psychomotor slowing as measured by the Salpêtrière retardation rating scale (SRRS) throughout the study.
The SRRS is a 15-item rating scale that measures psychomotor slowing. Each item can be scored from 0 to 4, thus the total ranging from 0 to 60, with lower scores representing better outcome. |
At baseline, day 3, post at day 5, and follow-up 1 week later | |
Primary | Proportion of responders in SRRS | Proportion of responders (>= 30% reduction from baseline SRRS) at day 3 and day 5. This will provide an additional categorical measure of who benefits from the intervention in terms of the main target (psychomotor slowing). | At baseline, day 3, post at day 5, and follow-up 1 week later | |
Secondary | Change in psychosis severity from baseline | Change in the Positive And Negative Symptom Scale (PANSS) from baseline, PANSS total score assesses the severity of positive, negative and general symptoms, ranging from 30-210 with higher scores indicating increased symptom severity, i.e. poorer outcome | At baseline, post at day 5, and follow-up 1 week later | |
Secondary | Change in negative symptoms from baseline | Change in the Brief Negative Symptom Scale (BNSS) from baseline, total score is used, ranging from 0-78 with higher values indicating poorer outcome, i.e. more negative symptom severity | At baseline, post at day 5, and follow-up 1 week later | |
Secondary | Change in catatonia severity from baseline | Observer based rating of catatonia severity with the Bush Francis Catatonia Rating Scale (BFCRS), total score of the BFCRS ranging 0-69, with higher scores indicating poorer outcome Observer based rating of catatonia severity with the Northoff Catatonia Rating Scale (NCRS), total score ranging 0-80, with higher scores indicating poorer outcome | At baseline, day 3, post at day 5, and follow-up 1 week later | |
Secondary | Change in parkinsonism severity from baseline | Observer based rating of parkinsonism severity with the Unified Parkinson Disease Rating Scale Part III (UPDRS), total score of the UPDRS ranging 0-104, with higher scores indicating poorer outcome | At baseline, day 3, post at day 5, and follow-up 1 week later | |
Secondary | Changes in neurological soft signs from baseline | Observer based rating of neurological soft signs with the Neurological Evaluation Scale (NES), total score ranging 0-82, with higher scores indicating poorer outcome | At baseline, post at day 5, and follow-up 1 week later | |
Secondary | Changes in dyskinesia from baseline | Observer based rating of dyskinesia with the Abnormal Involuntary Movement Scale (AIMS), 7-item scale with the total ranging fro 0-28, with higher scores indicating poorer outcome | At baseline, post at day 5 | |
Secondary | Changes in self-reported negative symptoms from baseline | Self-reported negative symptoms with the Self-evaluation of Negative Symptoms (SNS), total score ranging 0-40, with higher scores indicating poorer outcome | At baseline, post at day 5 | |
Secondary | Changes in self-reported catatonia symptoms from baseline | Self-reported catatonia symptoms with the Northoff Scale for Subjective Experience in Catatonia (NSSC), total score ranging 0-48, with higher scores indicating poorer outcome | At baseline, post at day 5 | |
Secondary | Changes in self-reported activity from baseline | Change in the International Physical Activity Questionnaire (IPAQ), the total score is used ranging from 0-70000 metabolic equivalent (MET) | At baseline, post at day 5 | |
Secondary | Change in objectively measured physical activity from baseline | Change in the activity levels using wrist actigraphy from baseline. Actigraphy is measured continuously from baseline to post and a sleep diary is collected to separate wake from sleep hours | Continuously from baseline to post at day 5 | |
Secondary | Change in dexterity from baseline | Change in the coin rotation task from baseline | At baseline, post at day 5 | |
Secondary | Change in grip strength from baseline | Change in grip strength measured with a grip force task | At baseline, post at day 5 | |
Secondary | Change in cortical excitability of the motor cortex from baseline | Changes in motor cortex excitability from beginning of day 1, end of day 1, end of day 3, and end of day 5 using a TMS paradigm of short interval intracortical inhibition (SICI), intracortical facilitation (ICF) and 1 mV motor evoked potentials (MEP). | Baseline before the first 3 TMS, baseline after the first 3 TMS, day 3 (after 9 TMS), post at day 5 (after 15 TMS) | |
Secondary | Change in social and community functioning | Change in Social and Occupational Functional Assesment Scale (SOFAS) from baseline, the score ranges from 0-100 with higher scores indicating better functioning, i.e. better outcome | Baseline, post at day 5 | |
Secondary | Change in global functioning | Change in Global Assessment of Functioning (GAF) from baseline, total score ranging 0-100 with higher scores indicating better functioning/outcome | Baseline, post at day 5 | |
Secondary | Change in functional capacity | Change in the Score of the brief version of the University of California, San Diego, Performance-Based Skills Assessment (UPSA-brief) assessment from baseline, higher scores indicating better function, the total score is used ranging 0-100 | Baseline, post at day 5 | |
Secondary | Change in DSM 5 Severity Scale of Dimensions | Change in expert rated DMS 5 Severity Scale of Dimensions from baseline. Eight symptom dimensions are rated from 0 to 4 (total 0-32), with higher scores indicating worse outcomes | Baseline, post at day 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Withdrawn |
NCT04068857 -
Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)
|
N/A | |
Withdrawn |
NCT04054973 -
L-arginine Study for Persistent Symptoms of Schizophrenia
|
Phase 2 | |
Recruiting |
NCT05968638 -
Ketogenic Diet in People With Schizophrenia
|
N/A | |
Recruiting |
NCT04113993 -
Bazedoxifene -Treatment for Women With Schizophrenia
|
Phase 4 | |
Completed |
NCT03671525 -
Cognitive Effects of Nimodipine in Patients With Schizophrenia
|
Early Phase 1 | |
Recruiting |
NCT04005794 -
Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training
|
N/A | |
Recruiting |
NCT05343598 -
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT06041646 -
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
|
Phase 4 | |
Completed |
NCT03338673 -
Brain Stimulation and Cognitive Training
|
N/A | |
Recruiting |
NCT05899348 -
iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
|
N/A | |
Recruiting |
NCT03943537 -
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
|
Phase 2 | |
Completed |
NCT04327843 -
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
|
Phase 3 | |
Completed |
NCT04637724 -
Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia
|
N/A | |
Completed |
NCT04526067 -
In-person vs. Remote Wellness Support
|
N/A | |
Active, not recruiting |
NCT05746494 -
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
|
N/A | |
Completed |
NCT03221270 -
Targeting Auditory Hallucinations With Alternating Current Stimulation
|
N/A | |
Recruiting |
NCT06176456 -
Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia
|
N/A | |
Recruiting |
NCT04907279 -
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
|